Tadalafil treats pulmonary arterial hypertension (PAH) by primarily inhibiting phosphodiesterase type 5 (PDE5). This enzyme normally breaks down cyclic guanosine monophosphate (cGMP), a crucial molecule that relaxes blood vessels. By blocking PDE5, Tadalafil increases cGMP levels.
Elevated cGMP leads to smooth muscle relaxation in pulmonary arteries, reducing vascular resistance. This lowers pulmonary arterial pressure and improves blood flow to the lungs. The result is decreased workload on the right ventricle of the heart, improving its function.
Beyond PDE5 inhibition, Tadalafil may also offer additional benefits. Studies suggest potential effects on inflammation and endothelial function, further contributing to PAH improvement. However, the primary mechanism remains PDE5 inhibition.
Dosage and response vary among patients. Your doctor will determine the appropriate Tadalafil dose based on your individual needs and response to treatment. Regular monitoring is vital to ensure optimal therapeutic effects and to manage potential side effects.
Remember, this information is for educational purposes only and does not constitute medical advice. Always consult your physician before starting or altering any medication regimen.
